Literature DB >> 28209463

Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes.

Rui-Xiang Zeng1, Sha Li2, Min-Zhou Zhang3, Xiao-Lin Li2, Cheng-Gang Zhu2, Yuan-Lin Guo2, Yan Zhang2, Jian-Jun Li4.   

Abstract

BACKGROUND: Remnant cholesterol (RC) is receiving increasing attention regarding its relation to cardiovascular risk. Whether RC is associated with periprocedural myocardial injury (PMI) following percutaneous coronary intervention (PCI) in type 2 diabetes (T2D) is currently unknown.
METHODS: We prospectively enrolled 1182 consecutive T2D patients who were scheduled for PCI but with baseline normal preprocedural cardiac troponin I (cTnI). Patients were divided according to their glycemic control status: group A [glycated hemoglobin (HbA1c)<7%, n=563] and group B (HbA1c≥7%, n=619). PMI was evaluated by cTnI analysis within 24h. The associations of preprocedural RC and the RC to high-density lipoprotein cholesterol ratio (RC/HDL-C) with PMI were investigated.
RESULTS: The associations of RC and RC/HDL-C with PMI were observed in group B (both p<0.05) but not in group A (both p>0.05). Patients in group B, a 1-SD increase of RC produced 30% and 32% increased risk for postprocedural cTnI>3× upper limit of normal (ULN) and >5×ULN, respectively. The odds ratios for RC/HDL-C were the highest compared with any cholesterol fractions including total cholesterol (TC)/HDL-C, low density lipoprotein cholesterol (LDL-C)/HDL-C, nonHDL-C/HDL-C, and triglyceride/HDL-C with 1.43 [95% confidence interval (CI): 1.10-1.88] for >3× ULN and 1.49 (95% CI: 1.13-1.97) for >5× ULN. However, no such associations were found in group A. Furthermore, patients with RC >27.46mg/dL (third tertile) [RC≤14.15mg/dL (first tertile) as reference] were associated with a 1.57-fold and 2-fold increased risk for >3× ULN and >5× ULN in group B, respectively.
CONCLUSIONS: RC and RC/HDL-C might be valuable, independent predictors for PMI in poorly-controlled diabetic patients undergoing PCI.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Percutaneous coronary intervention; Periprocedural myocardial injury; Remnant cholesterol; Remnant cholesterol to HDL cholesterol ratio; Type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28209463     DOI: 10.1016/j.jjcc.2016.12.010

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  6 in total

1.  A machine learning-based approach for the prediction of periprocedural myocardial infarction by using routine data.

Authors:  Yao Wang; Kangjun Zhu; Ya Li; Qingbo Lv; Guosheng Fu; Wenbin Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

2.  Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.

Authors:  Pijun Yan; Yong Xu; Ying Miao; Xue Bai; Yuru Wu; Qian Tang; Zhihong Zhang; Jiong Yang; Qin Wan
Journal:  Acta Diabetol       Date:  2021-06-28       Impact factor: 4.280

3.  Importance of lipid ratios for predicting intracranial atherosclerotic stenosis.

Authors:  Wen-Song Yang; Rui Li; Yi-Qing Shen; Xing-Chen Wang; Qing-Jun Liu; Hai-Yang Wang; Qi Li; Guo-En Yao; Peng Xie
Journal:  Lipids Health Dis       Date:  2020-07-04       Impact factor: 3.876

4.  Gensini score values for predicting periprocedural myocardial infarction: An observational study analysis.

Authors:  Yao Wang; Qingbo Lv; Ya Li; Songzan Chen; Liding Zhao; Guosheng Fu; Wenbin Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

5.  Total/high density lipoprotein cholesterol and cardiovascular disease (re)hospitalization nadir in type 2 diabetes.

Authors:  Dahai Yu; Yamei Cai; Rui Qin; Jonathan Graffy; Daniel Holman; Zhanzheng Zhao; David Simmons
Journal:  J Lipid Res       Date:  2018-06-29       Impact factor: 5.922

6.  Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease.

Authors:  Yang Zou; Chong Hu; Maobin Kuang; Yuliang Chai
Journal:  BMC Gastroenterol       Date:  2022-03-24       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.